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ABSTRACT
Background In phenylketonuria, genetic heterogeneity,
frequent compound heterozygosity, and the lack of
functional data for phenylalanine hydroxylase genotypes
hamper reliable phenotype prediction and individualised
treatment.
Methods A literature search revealed 690 different
phenylalanine hydroxylase genotypes in 3066
phenylketonuria patients from Europe and the Middle
East. We determined phenylalanine hydroxylase function
of 30 frequent homozygous and compound heterozygous
genotypes covering 55% of the study population,
generated activity landscapes, and assessed the
phenylalanine hydroxylase working range in the
metabolic (phenylalanine) and therapeutic
(tetrahydrobiopterin) space.
Results Shared patterns in genotype-specific functional
landscapes were linked to biochemical and
pharmacological phenotypes, where (1) residual activity
below 3.5% was associated with classical
phenylketonuria unresponsive to pharmacological
treatment; (2) lack of defined peak activity induced loss
of response to tetrahydrobiopterin; (3) a higher cofactor
need was linked to inconsistent clinical phenotypes and
low rates of tetrahydrobiopterin response; and (4)
residual activity above 5%, a defined peak of activity,
and a normal cofactor need were associated with
pharmacologically treatable mild phenotypes. In addition,
we provide a web application for retrieving country-
specific information on genotypes and genotype-specific
phenylalanine hydroxylase function that warrants
continuous extension, updates, and research on demand.
Conclusions The combination of genotype-specific
functional analyses with biochemical, clinical, and
therapeutic data of individual patients may serve as a
powerful tool to enable phenotype prediction and to
establish personalised medicine strategies for dietary
regimens and pharmacological treatment in
phenylketonuria.
INTRODUCTION
The large number of phenylalanine hydroxylase
(PAH) mutations (625 entries (public total), http://
www.hgmd.org), the high incidence of compound
heterozygosity, and the variability in distribution of
common mutations between ethnic groups and
geographical areas makes phenylketonuria (PKU,
OMIM #261600) a genetic disease with pronounced
allelic heterogeneity. PKU caused by deficiency of the
PAH enzyme1 2 has an overall incidence of 1:10 000
in European descendants, which varies considerably
among different populations.3 4
The clinical phenotype of PKU is driven by
mutation-induced loss of PAH function. A con-
tinuum of residual in vivo PAH enzyme activity
determines the clinical picture, ranging from severe
classical PKU via mild PKU to mild hyperphenylala-
ninaemia (MHP) with increasing activity and
decreasing blood phenylalanine concentrations
from severe to mild.5 6 In addition to standard
treatment using a phenylalanine-restricted diet, a
significant proportion of patients is amenable to
pharmacological treatment with the PAH cofactor
tetrahydrobiopterin (BH4).
7 8 This constitutes a
superordinate phenotype that requires residual
PAH activity9 10 and further adds to the phenotypic
variability of PAH deficiency.11
Mutations in the PAH gene can induce PAH
loss-of-function by different molecular mechanisms.
Splicing mutations, nonsense mutations, and
out-of-frame indels lead to a complete loss of the
PAH protein, whereas missense mutations as well as
some in-frame indels still lead to the production of
variant PAH proteins. Loss of function of variant
PAH is a consequence of loss of specific enzymatic
activity and/or loss of effective intracellular PAH
protein amount caused by protein misfolding.12–16
Databases such as PAHdb (http://www.pahdb.
mcgill.ca) and BIOPKU (http://www.biopku.org)
provide general information on PAH mutations and
associated phenotypes; however, there is no data-
base access on occurrence and frequency of geno-
types in individual countries. A significant gap of
knowledge concerns the enzymatic function asso-
ciated with PAH genotypes. Available data on
residual PAH enzyme activity is limited to single
mutations expressed in different cellular systems
using diverse enzyme assay protocols.5 13 16–19
Non-invasive functional assays, for example, in
blood cells, are not feasible because metabolic PAH
function is restricted to the liver. Therefore, PAH
activity is commonly determined by means of
experimental in vitro systems. Since calculated
enzyme activities based on heterogeneous data on
single mutations do not reliably reflect residual
activity in the patient, a consistent model system to
assess PAH enzyme function arising from two dif-
ferent alleles reflecting the most common geno-
types is needed. In addition, previous work has
revealed that PAH function depends on the meta-
bolic phenotype and a potential pharmacologic
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administration of BH4.
20 Genotype-specific data on PAH func-
tion assessed at different substrate and cofactor concentrations
may thus assist physicians in managing the dietary treatment
and in predicting the probability of pharmacological response in
clinical practice. In order to provide this information, we (1)
mapped the most common reported PAH genotypes in Europe
and Middle East; (2) determined PAH residual function of fre-
quent homozygous and compound heterozygous genotypes in a
cell based model; (3) generated activity landscapes; and (4)
assessed the PAH working range.
This study provides the first comprehensive dataset on PAH
function arising from the most common genotypes carried by
PKU patients in Europe and the Middle East. PAH enzyme
activity assessed at a wide range of phenylalanine and BH4 con-
centrations mirrors metabolic and therapeutic conditions and
thus provides information on the optimal range of substantial
PAH enzyme function in PKU patients. This may allow for
genotype-specific optimisation of phenylalanine restricted
dietary regimens and treatment with BH4.
METHODS
Data sources for PAH genotypes and phenotypes
Data from 24 publications reporting PAH genotypes in 19 coun-
tries in Europe and the Middle East and unpublished data from
German and French medical centres were analysed (see online
supplementary table S1). Types and frequencies of mutations
were obtained from the Human Gene Mutation Database
(http://www.hgmd.org), the PAHdb (http://www.pahdb.mcgill.ca)
and the BIOPKU database (http://www.biopku.org). Data on
PKU clinical phenotypes and BH4 responsiveness were obtained
from BIOPKU.
Assay of PAH activity
In this study, we analysed 30 PAH genotypes consisting of 18 PAH
missense mutations and one intronic mutation c.1066-11G>A
(previously known as IVS10-11G>A),16 which results in the inser-
tion of three amino acids (p.Gln355_Tyr356insGlyLeuGln) (see
online supplementary table S2). Constructs carrying PAH muta-
tions were co-expressed in COS-7 cells reflecting PAH genotypes.
The multi-well PAH activity assay for determination of activity
landscapes from eukaryotically expressed PAH was performed as
previously described for recombinantly expressed and purified
PAH20 with modifications. Varying volumes of a 5 mM
L-phenylalanine (Sigma-Aldrich) solution and 22.35 mM
NaHEPES, pH 7.3, were injected (FLUOstar OPTIMA, BMG
Labtech) into all wells of a 96-well plate. This resulted in 12
columns of varying L-phenylalanine concentrations (0–4000 mM).
A reaction buffer containing 1 mg/mL catalase (Sigma-Aldrich),
10 mM ferrous ammonium sulfate (Sigma-Aldrich), and 20 mL
protein lysate per well was subsequently injected in all 96 wells.
After pre-incubation for 5 min, the reaction was triggered by the
addition of variable concentrations of BH4 (6R-L-erythro-5,6,7,8-
tetrahydrobiopterin, Schircks Laboratories) (0–500 mM, rows of
the 96-well plate) stabilised in 100 mM dithiothreitol (DTT,
Sigma-Aldrich). The PAH activity assay was incubated at 25°C for
15 min and stopped by acetic acid. All concentrations mentioned
refer to the final concentration in a 200 mL reaction mixture. The
formation of the L-Tyr product was quantified by high perform-
ance liquid chromatography (HPLC) using a Hypersil ODS-2
column (ThermoScientific). All PAH activity landscapes were
assayed in three independent experiments and the data were com-
bined. Genotypes were divided into three groups based on PAH
activity determined at the area of peak activity (group 1, PAH
residual activity <3.5%; group 2, ≥3.5% and <5%; group 3
≥5%). If no area of peak activity was delimitable, activity at stand-
ard conditions (L-phenylalanine, 1 mM; BH4, 75 mM) was used
for classification.
PAH activity landscapes
PAH activity landscapes were generated as previously described20
with modifications. The dataset obtained from the multi-well PAH
activity assayed in a 12×8 matrix corresponding to 12 different
L-phenylalanine concentrations (0–4000 mM; columns) at eight
BH4 concentrations (0–500 mM; rows) was loaded into an analysis
software (GraphPad Prism 5.0a). Non-linear regression analysis
allowed for expanding the dataset for BH4 concentrations from
eight measured to 200 interpolated values following a substrate
inhibition curve. This resulted in a 12×200 matrix of activity
values. For the generation of landscapes, the data matrix was
exported to the free software package R (http://www.r-project.
org). In order to draw a smooth surface of the landscape, the func-
tion interp.loess from an additional R package tgp (http://cran.
r-project.org/web/packages/tgp/index.html) was applied, which
interpolates between two data points by using local polynomial
regression fitting to find a function between them. This resulted in
a matrix of 400×400 data points, which was then depicted as a
smooth landscape plot using the function image.plot from package
fields (http://cran.r-project.org/web/packages/fields/index.html). To
facilitate calculation of landscapes, a web application (http://
pah-activitylandscapes.org/calcLandscapes.php) was set up accept-
ing comma-separated files and automatically colouring landscapes
depending on the measured and interpolated enzyme activity
values.
Web application
An interactive website provides country- and region-specific infor-
mation on PAH genotypes and links genotypes to graphical repre-
sentation of activity landscapes (http://pah-activitylandscapes.org).
The site will be updated and users can request the generation of
landscapes of additional genotypes.
More detailed information on material and methods is avail-
able in the online supplementary data.
RESULTS
PAH genotypes in Europe and the Middle East
We performed a comprehensive PubMed literature search to
determine the frequency and region-specific distribution of PAH
genotypes. The study focused on Europe and the Middle East
owing to the shared ethnic background in this region and data
from 20 countries spanning from Portugal to Iran were selected
for evaluation (figure 1 and see online supplementary table S1).
The 3066 PKU patients of this study population displayed 690
different genotypes based on 264 mutations (http://
pah-activitylandscapes.org).
The type and frequency of single PAH mutations constituting
the genotypes in our study cohort matched well with the fre-
quency documented in gene databases (table 1), and mutations
considered as prevalent in the European population4 covered
80.3% of alleles in our cohort (see online supplementary table
S2). The predominant variant p.Arg408Trp (37%) occurred in
all countries except Lebanon and Cyprus, while the second
most common variant, p.Gln355_Tyr356insGlyLeuGln (10.2%),
did not appear in Croatian, Slovenian, and Swedish populations.
A region-specific distribution was also observed for other muta-
tions (see online supplementary figure S1).
The most common full PAH genotypes for eight countries are
shown in figure 1. Of all genotypes analysed, 9% were homozy-
gous, 91% compound heterozygous, and 49% of PKU patients
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carried missense mutations on both alleles. The 30 most fre-
quent genotypes encoding expressible PAH proteins from both
alleles (table 1) covered 55% of patients in our study population
(BIOPKU, 33%; PAHdb, 18%). The frequency of these geno-
types was high in Croatia (88%), Turkey (87%), and France
(61%) and lower in Slovenia (11%) and Spain (10%). The geno-
type p.[Arg408Trp];[Arg408Trp] occurred in 21% of patients
and was predominant in Northern and Eastern Europe
(Lithuania, Norway, Poland, Slovakia), followed by homozygous
p.Gln355_Tyr356insGlyLeuGln (5.2%), which was frequent in
the Middle East (Iran, Turkey, Israel, Lebanon, Armenia).
Genotype frequencies in five geographical regions (Northern
Europe, Southern Europe, Western Europe, Eastern Europe, and
Middle East) and country-specific frequencies are summarised in
online supplementary figure S2 and are available at http://
pah-activitylandscapes.org.
Residual PAH function of wild-type PAH and
frequent PAH genotypes
Ex vivo assessment of PAH enzyme activity in liver tissue
requires unjustifiable invasive procedures. Thus, we aimed to
provide a cellular model that quantifies genotype-specific
residual PAH function and takes into account PAH protein
homeostasis and the metabolic environment. PAH activity of
Figure 1 Phenylalanine hydroxylase (PAH) genotypes in Europe and Middle East. Countries included in the study are marked in blue. The graphs
below show the frequencies of the most common PAH genotypes in individual countries for which data from more than 100 patients were available.
In case the effect of intronic mutation on protein level is not known, the substitution at DNA level was used. The map was created using http://
www.stepmap.de.
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cells expressing variant PAH encoded by both alleles of individ-
ual PAH genotypes was determined at the physiological to
pathological range of phenylalanine concentrations (25–4000
mM) as well as a physiological to supratherapeutic range of BH4
cofactor concentrations (9–500 mM).
The activity landscape of the wild-type enzyme showed a peak
maximum enzyme activity of 72 658 pmol L-Tyr/min x mg
protein at 431 mM L-phenylalanine and 130 mM BH4 (figure 2,
see online supplementary figure S3 and table 2). This was in line
with previous results for purified wild-type PAH protein
expressed in Escherichia coli.20 The optimal working range for
L-phenylalanine spanned from 135 mM ([S]0.5) to 747 mM (Ki).
Thus, the PAH enzyme displayed very low activity at
L-phenylalanine concentrations <120 mM and a broader range
of considerable activity at higher L-phenylalanine concentrations,
even >600 mM. In addition, the wild-type enzyme showed high
activity at cofactor concentrations between 30 mM ([C]0.5) and
294 mM (Ki). At L-phenylalanine concentrations above the thera-
peutic threshold of 360 mM21 the enzyme showed a need for
increased BH4 concentrations to maintain the same level of
activity.
Residual PAH activity of eukaryotically expressed genotypes
(table 2, see online supplementary tables S3 and S4) ranged
from 1.7% (p.[Arg408Trp];[Arg408Trp]) to 11% (p.
[Arg261Gln];[Arg261Gln]) of wild-type PAH, which fits well
with the threshold of 15% PAH activity related to metabolic
decompensation.2 Genotypes were divided into three groups:
those with PAH residual activity <3.5% (group 1, n=9); those
Table 1 PAH genotypes in PKU patients from Europe and the Middle East and associated frequencies
Frequency [%]
Allele 1 Allele 2 Our study* BIOPKU† PAHdb†
1‡ p.Arg408Trp p.Arg408Trp 21.0 10.7 5.0
2‡ p.Gln355_Tyr356insGlyLeuGln p.Gln355_Tyr356insGlyLeuGln 5.2 2.3 1.5
3‡ p.Arg408Trp p.Arg158Gln 2.9 1.7 0.8
4‡ p.Arg408Trp p.Gln355_Tyr356insGlyLeuGln 2.8 1.5 0.2
5‡ p.Arg261Gln p.Arg261Gln 2.1 1.7 1.7
6‡ p.Arg408Trp p.Ala403Val 2.0 1.2 –
7 p.Arg408Trp c.1315+1G>A 2.0 1.5 1.7
8‡ p.Arg408Trp p.Pro281Leu 1.7 1.0 0.5
9‡ p.Arg408Trp p.Arg261Gln 1.6 1.4 1.8
10‡ p.Pro281Leu p.Pro281Leu 1.6 0.9 1.2
11‡ p.Arg408Trp p.Tyr414Cys 1.4 1.1 1.2
12‡ p.Arg408Trp p.Ala300Ser 1.3 0.8 0.2
13‡ p.Leu48Ser p.Leu48Ser 1.1 0.8 –
14‡ p.Arg408Trp p.Ile306Val 1.0 0.5 –
15‡ p.Arg261Gln p.Gln355_Tyr356insGlyLeuGln 0.9 0.7 0.5
16‡ p.Arg408Trp p.Glu390Gly 0.8 0.6 0.2
17‡ p.Arg408Trp p.Arg252Trp 0.7 0.6 0.5
18‡ p.Arg408Trp p.Leu48Ser 0.7 1.0 0.3
19‡ p.Arg252Trp p.Arg252Trp 0.6 0.4 0.2
20‡ p.Arg408Trp p.Arg297His 0.6 0.2 –
21‡ p.Pro281Leu p.Gln355_Tyr356insGlyLeuGln 0.6 0.3 0.3
22‡ p.Ala300Ser p.Gln355_Tyr356insGlyLeuGln 0.6 0.4 0.2
23 p.Tyr414Cys c.1315+1G>A 0.6 0.6 1.7
24‡ c.441+5G>T c.441+5G>T 0.5 0.2 0.2
25‡ p.Leu48Ser p.Gln355_Tyr356insGlyLeuGln 0.5 0.4 0.3
26‡ p.Leu48Ser p.Arg261Gln 0.5 0.5 0.2
27‡ p.Arg408Trp p.Val245Ala 0.5 0.3 0.3
28‡ p.Leu48Ser p.Arg158Gln 0.4 0.3 0.2
29‡ p.Ile65Thr p.Gln355_Tyr356insGlyLeuGln 0.4 0.4 0.6
30 p.Arg408Trp g.47563_51794del4232 g.56161_56430ins268 0.4 – –
31‡ p.Arg408Trp p.Ile283Phe 0.4 0.2 0.3
32‡ p.Arg408Trp p.Val388Met 0.4 0.2 –
33‡ p.Arg408Trp p.Arg241His 0.4 0.3 –
34 p.Arg261Gln c.1315+1G>A 0.4 0.4 0.8
35 p.Arg408Trp p.Phe55fs 0.4 0.4 0.2
36‡ p.Arg408Trp p.Leu348Val 0.4 0.4 0.2
Total number of patients (n) 3066 7453 658
Population of patients covered by 30 genotypes (%) 55.0 32.8 18.4
Population of patients covered by 36 genotypes (%) 59.4 35.9 22.9
The table shows the 36 most frequent genotypes in Europe and the Middle East and their relative frequencies.
*Frequencies of genotypes retrieved from the literature (PubMed search) and obtained via personal communications.
†Frequencies of genotypes retrieved from public databases: BIOPKU (query 23 April 2014) and PAHdb (query 19 April 2014).
‡30 PAH genotypes encoding expressible PAH proteins from both alleles selected for experimental studies.
PAH, phenylalanine hydroxylase; PKU, phenylketonuria.
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with activities ≥3.5% and <5% (group 2, n=3); and those
≥5% (group 3, n=18) (table 2, figures 3–5). Group 3 contained
all genotypes with mutations known to be associated with mild
clinical phenotypes (p.Val245Ala, p.Ala300Ser, p.Glu390Gly, p.
Ala403Val). Although p.Gln355_Tyr356insGlyLeuGln is com-
monly considered a null mutation,16 it reached up to 5% of
activity in the homozygous state, suggesting preservation of
some residual function in patients. Taking into consideration the
30 most frequent genotypes, 37% of PKU patients in this
cohort carried a genotype associated with low residual PAH
function <5%, and 19% of patients can be expected to have a
considerable residual enzyme function with activities >5%.
Armenia, Croatia, Iran, Lithuania, Poland, Slovakia and Turkey
showed a predominance of severe genotypes, whereas France,
Italy, and the Czech Republic are countries where milder bio-
chemical phenotypes are more frequent than severe ones (see
online supplementary table S5).
Peak enzyme activity and optimal working
range of PAH genotypes
We aimed to identify the metabolic context for best PAH function.
Peak PAH enzyme activity— that is, the relation of optimal
enzyme activity to substrate and cofactor concentrations—consti-
tutes an important functional feature in phenylalanine metabolism
and is of clinical relevance. We defined the working optimum for
the PAH enzyme as the range of activity between [S]0.5 and (Ki) for
the substrate and between [C]0.5 and (Ki) for the cofactor— that is,
the ranges of all activities above 50% (table 2 and see online sup-
plementary figure S4). Functional activity landscapes from group 1
displayed very low activity with no defined peak (figure 3). In
group 2, enzyme activities were still low but an area of peak activ-
ity mapping to the area of wild-type PAH was delimitable
(figure 4). Group 3 genotypes showed considerable residual activ-
ities and delimitable peak areas with the exceptions of p.
[Pro281Leu];[Gln355_Tyr356insGlyLeuGln] and homozygous p.
[Gln355_Tyr356insGlyLeuGln ];[Gln355_Tyr356insGlyLeuGln]
(figure 5). However, the position and shape of areas of peak
enzyme activity showed large variation within this group. The sub-
strate concentration at peak activity ranged from 251–882 mM for
genotypes that displayed a defined peak area. For p.[Ile306Val];
[Arg408Trp], p.[Ala403Val];[Arg408Trp], and p.[Tyr414Cys];
[Arg408Trp] peak activity mapped to significantly lower phenyl-
alanine concentrations than observed for the wild-type. These left-
shifts were associated with higher apparent affinity of the enzymes
towards the substrate, as reflected by lower values for [S]0.5.
On the other hand, p.[Arg261Gln];[Arg261Gln], p.[Arg261Gln];
[Arg408Trp], p.[Arg261Gln];[Gln355_Tyr356insGlyLeuGln], and
p.[Arg297His];[Arg408Trp] led to peak activities at higher phenyl-
alanine concentrations associated with lower apparent affinity of
the enzyme towards the substrate, as reflected by higher values for
[S]0.5. All but one of these genotypes contained p.Arg261Gln. All
other genotypes displayed peak activities at L-phenylalanine con-
centrations in the wild-type range.
The working range of wild-type PAH with respect to the
substrate covered an interval of >600 mM. Broadening of
the working range of the PAH enzyme (interval >900 mM),
denoting high residual enzyme activity over a wide range of
phenylalanine concentrations, was observed for p.[Leu48Ser];
[Arg261Gln], p.[Arg261Gln];[Arg261Gln], p.[Arg261Gln];
[Gln355_Tyr356insGlyLeuGln], and p.[Arg297His];[Arg408Trp].
Three of these genotypes contained the allele p.Arg261Gln
and 4.1% of the patients in our study population carried a geno-
type associated with this activity landscape feature. On the other
hand, a narrow working range leading to considerable PAH
activity only in a tight window of substrate concentrations




[Ala403Val];[Arg408Trp], and p.[Tyr414Cys];[Arg408Trp], with
p.Leu48Ser and p.Arg408Trp being the leading mutations in this
group. These occurred in 7.7% of the patients. Genotypes
showing a left-shift always showed a smaller area of enzyme activ-
ity, but not all genotypes with narrow working ranges were left-
shifted. Thus, high affinity towards the substrate and a smaller area
of phenylalanine-dependent activity range may be due to inde-
pendent mechanisms.
The cofactor concentration at peak activity ranged from
94–409 mM. All genotypes with a residual activity
≥3.5% and peak enzyme activities at lower cofactor concentra-
tions than the wild-type (p.[Leu48Ser];[Arg261Gln], p.
[Arg261Gln];[Arg261Gln], p.[Arg261Gln];[Arg408Trp], p.
[Arg297His];[Arg408Trp], p.[Glu390Gly];[Arg408Trp], p.
[Ala403Val];[Arg408Trp]) included the alleles p.Arg261Gln or
p.Arg408Trp. Interestingly, a shift towards lower cofactor con-
centrations was not associated with an increase in the apparent
affinity of the enzymes towards the cofactor as reflected by




and p.[Leu348Val];[Arg408Trp] led to peak activities at higher
BH4 concentrations. It is of note that the presence of the allele
p.Gln355_Tyr356insGlyLeuGln correlated with a shift of peak
activity towards higher BH4 concentrations when residual
activity is ≥5%. Most of these genotypes contained a mutation
previously classified as being inconsistently linked to clinical
phenotypes (p.Leu48Ser, p.Ile65Thr, p.Ala300Ser) (see online
supplementary figure S5). Patients carrying these genotypes
may need higher cofactor concentrations for optimal enzyme
activity. All other genotypes induced peak activities at similar
BH4 concentrations than the wild-type.
Impact of PAH function on clinical phenotypes
Next, we linked functional data to clinical phenotypes retrieved
from BIOPKU (see online supplementary figure S5). Group 1 geno-
types with very low PAH activities lacking a well-defined peak of
activity were consistently associated with BH4 non-responsive clas-
sical PKU. One exception, p.[Arg241His];[Arg408Trp], showed a
Figure 2 Phenylalanine hydroxylase (PAH) activity landscape of
human wild-type (WT) PAH expressed in cell culture. Data for PAH
enzyme activity assayed at varying L-phenylalanine and BH4
concentrations were interpolated and depicted by a colour code. With
increasing substrate concentrations, more BH4 is needed to maintain
the same level of enzyme activity (solid line).
Danecka MK, et al. J Med Genet 2015;52:175–185. doi:10.1136/jmedgenet-2014-102621 179
Genotype-phenotype correlations
group.bmj.com on May 3, 2017 - Published by http://jmg.bmj.com/Downloaded from 
leading phenotype of mild PKU (70% of patients), yet responsive-
ness to BH4 was only assessed for two cases. Group 2 genotypes,
all displaying intermediate residual activity and a defined area of
peak activity, showed phenotypic heterogeneity with both mild and
classical PKU phenotypes and a significant share of patients
responding to BH4. Among group 3, two subgroups were analysed.
Group 3 genotypes without area of peak activity (p.[Pro281Leu];
[Gln355_Tyr356insGlyLeuGln], p.[Gln355_Tyr356insGlyLeu
Gln];[Gln355_Tyr356insGlyLeuGln]), leading to a total loss of
landscape architecture, were mainly associated with classical PKU
and a low response rate to BH4 (10–25%). These also displayed
rather low residual activities within this group (5.1%, 5.7%). Yet
other genotypes with residual activities in the same range, but
showing a defined area of peak activity, displayed higher response
rates suggesting that a loss of landscape architecture is linked to a
loss of BH4 responsiveness.
Group 3 genotypes with peak activity were predominantly asso-
ciated with MHP or mild PKU and high response rates to cofactor




with the predominance of classical PKU and unresponsiveness to
pharmacological treatment. Interestingly, three of these genotypes
contained p.Gln355_Tyr356insGlyLeuGln and three of these geno-
types were associated with peak activities at increased cofactor con-
centrations. Therefore, dosages used in standard response tests may
not be sufficient to meet the high need for BH4 of patients carrying
one of these genotypes.
Taken together, the results from this study indicate that
residual PAH activity alone is not a reliable predictor of the clin-
ical phenotype but other factors may be taken into account.










at peak activity ‡[S]0.5—Ki
§BH4
concentration
at peak activity ¶[C]0.5—Ki
WT 72 658±13 134 100 431±23 135–747 130±11 30–294
p.[Leu48Ser];[Leu48Ser] 3 4769±411 6.6 351±3 92–533 146±11 37–463
p.[Leu48Ser];[Arg158Gln]** 2 3041±134 4.2 330±7 78–542 200±15 89–458
p.[Leu48Ser];[Arg261Gln] 3 6229±61 8.6 501±17 146–1164 100±1 31–302
p.[Leu48Ser];[Arg408Trp] 2 2534±118 3.5 351±0 90–543 268±13 33–432
p.[Leu48Ser];[Gln355_Tyr356insGlyLeuGln] 3 5468±337 7.5 391±9 103–556 235±73 32–432
p.[Ile65Thr];[Gln355_Tyr356insGlyLeuGln] 3 4978±185 6.8 441±30 119–605 409±76 43–424
p.[Arg158Gln];[Arg408Trp]†† 1 2470±708 n. a. n. a. n. a. n. a. n. a.
p.[Arg241His];[Arg408Trp]†† 1 2071±156 n. a. n. a. n. a. n. a. n. a.
p.[Val245Ala];[Arg408Trp] 3 7486±360 10 391±9 120–643 157±12 34–468
p.[Arg252Trp];[Arg252Trp]†† 1 2699±74 n. a. n. a. n. a. n. a. n. a.
p.[Arg252Trp];[Arg408Trp]†† 1 2267±202 n. a. n. a. n. a. n. a. n. a.
p.[Arg261Gln];[Arg261Gln] 3 8031±861 11 762±10 283–1314 94±2 28–249
p.[Arg261Gln];[Arg408Trp] 3 4598±351 6.3 752±6 252–1023 99±14 35–258
p.[Arg261Gln];[Gln355_Tyr356insGlyLeuGln] 3 6013±903 8.3 802±119 197–1118 149±39 32–247
p.[Pro281Leu];[Pro281Leu]†† 1 2265±252 n. a. n. a. n. a. n. a. n. a.
p.[Pro281Leu];[Arg408Trp]†† 1 2297±117 n. a. n. a. n. a. n. a. n. a.
p.[Pro281Leu];[Gln355_Tyr356insGlyLeuGln]†† 3 4163±663 5.7 n. a. n. a. n. a. n. a.
p.[Ile283Phe];[Arg408Trp]†† 1 2534±307 n. a. n. a. n. a. n. a. n. a.
p.[Arg297His];[Arg408Trp] 3 7162±123 9.8 882±141 319–1938 99±11 29–219
p.[Ala300Ser];[Arg408Trp] 3 3819±375 5.2 391±4 120–615 135±11 30–461
p.[Ala300Ser];[Gln355_Tyr356insGlyLeuGln] 3 5011±439 6.9 431±11 131–576 219±70 34–429
p.[Ile306Val];[Arg408Trp] 3 4494±453 6.2 271±6 64–513 105±6 52–298
p.[Leu348Val];[Arg408Trp] 3 5700±395 7.8 511±31 156–1046 215±29 31–331
p.[Val388Met];[Arg408Trp] 3 5365±110 7.4 361±4 112–730 159±8 32–371
p.[Glu390Gly];[Arg408Trp] 3 6005±314 8.3 501±7 150–770 100±15 30–288
p.[Ala403Val];[Arg408Trp] 3 6444±1054 8.8 251±14 52–510 100±0 44–226
p.[Arg408Trp];[Arg408Trp]†† 1 1273±157 n. a. n. a. n. a. n. a. n. a.
p.[Arg408Trp];[Gln355_Tyr356insGlyLeuGln]†† 1 2919±453 n. a. n. a. n. a. n. a. n. a.
p.[Tyr414Cys];[Arg408Trp] 2 3560±271 4.9 301±3 87–528 139±9 33–404
p.[Gln355_Tyr356insGlyLeuGln]; [Gln355_Tyr356insGlyLeuGln]†† 3 3710±369 n. a. n. a. n. a. n. a. n. a.
The table summarises height and position of peak PAH enzyme activities and the optimal working ranges arising from group 1, 2 and group 3 PAH genotypes. Residual PAH activity at
standard conditions is summarised in table S3.
*Peak PAH enzyme activity is given as [pmol L-tyrosine/min x mg protein]±SEM.
†L-Phenylalanine concentration at peak activity is given as [mM]±SEM.
‡[S]0.5—Ki indicates the optimal PAH working range (>50% of the respective residual activity) as to substrate concentrations.
§BH4 concentration at peak activity is given as [mM]±SEM.
¶[C]0.5—Ki indicates the optimal PAH working range (>50% of the respective residual activity) as to cofactor concentrations.
**Calculated parameters refer to a peak mapping to the area of WT peak PAH activity; a second area of high activity was observed for L-phenylalanine > 2500 mM.
††Calculated parameters refer to the area of highest PAH activity; a defined peak area was not delimitable.
n. a., not applicable, no peak area was delimitable.
PAH, phenylalanine hydroxylase; WT, wild-type.
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Our analyses led to the recognition of the following orienteer-
ing rules for the implementation of personalised medicine strat-
egies. (1) Low residual activity is associated with mostly BH4
unresponsive classical PKU. (2) Lack of a defined area of peak
activity leads to a loss of response to BH4. (3) The occurrence
of inconsistent clinical phenotypes with low rates of BH4
response is linked to a higher need for BH4. (4) Residual activity
>5%, a defined peak of activity, and normal need for BH4 are
associated with mostly BH4 responsive mild PKU or MHP.
Moreover, the occurrence of the allele p.Arg261Gln is
often associated with inconsistent phenotypes, whereas the
allele p.Gln355_Tyr356insGlyLeuGln is linked to a higher
cofactor need.
DISCUSSION
The healthcare practitioner’s view on genetic disease underwent
change during the last decade. Genotyping has become easier
and databases provide access to a wealth of data related to
genetic variation. In addition, an increasing number of therapies
evolved from an improved understanding of the molecular basis
of maladies. After diagnosis of an inherited disease, families
request reliable prediction of the clinical phenotype and the long
Figure 3 Group 1 phenylalanine hydroxylase (PAH) activity landscapes. The interpolated residual enzyme activities after expression of homozygous
and compound heterozygous PAH genotypes were colour-coded and given as a function of different L-phenylalanine and BH4 concentrations. Group
1 refers to genotypes associated with a PAH residual activity of <3.5% of the wild-type.
Figure 4 Group 2 phenylalanine hydroxylase (PAH) activity landscapes. The interpolated residual enzyme activities after expression of homozygous
and compound heterozygous PAH genotypes were colour-coded and given as a function of different L-phenylalanine and BH4 concentrations. Group
2 refers to genotypes associated with a PAH residual activity of ≥3.5% and <5% of the wild-type.
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Figure 5 Group 3 phenylalanine hydroxylase (PAH) activity landscapes. The interpolated residual enzyme activities after expression of homozygous
and compound heterozygous PAH genotypes were colour-coded and given as a function of different L-phenylalanine and BH4 concentrations. Group
3 refers to genotypes associated with a PAH residual activity ≥5% of the wild-type.
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term outcome. In the specific case of PKU, the approval of a drug
providing the first pharmacological therapy for the disorder7 22 23
added a new dimension to diagnosis and treatment. Clinical gen-
etics at the service of patients faces the challenge of combining
empirical evidence buried in databases with functional evidence
from basic research. To this end, an experimental basis to assess
molecular consequences of genetic alteration and to generate
solid functional data considering full genotypes is required.
In this study, we aimed to provide a tool for the thorough
analysis of genotype-related PAH function for PKU patients in
Europe and the Middle East. A comprehensive literature search
revealed that the 30 most frequent genotypes represent 55% of
patients. Thus, the experimental investigation of a convenient
number of genotypes can cover significant shares of a given
population and thus provide meaningful information to physi-
cians in clinical practice.
Residual enzyme activities reported for a number of single
PAH mutations16 24 25 do not reflect the patient’s situation since
values well above 50% are not expected to produce a biochem-
ical and clinical phenotype. A study investigating in vivo PAH
function provided evidence for a threshold, where enzyme activ-
ities >15% were linked to normal biochemical parameters and
thus normal function.2 Moreover, it is well known that conse-
quences arising from full genotypes consisting of both alleles
differ from the average induced by the two mutations involved
and that proteins arising from different alleles influence
each other—a phenomenon termed interallelic complementa-
tion.26–28 Furthermore, although residual PAH enzyme activity
assessed at fixed substrate and cofactor conditions for single
mutations shows a general correlation with clinical severity and
BH4 responsiveness,
29 30 there is still significant inconsistency
that hampers solid phenotype prediction in clinical care. This
prompted us to develop a model system that mimics the cellular
situation in carriers of both homozygous and compound hetero-
zygous genotypes. Our system was calibrated at the equilibrium
of PAH synthesis and degradation and takes into account the
contributions of protein misfolding and accelerated degrad-
ation.12 13 31 In the liver, the PAH enzyme is subjected to fluctu-
ation of phenylalanine and, under treatment, of BH4. In order
to reflect the situation in vivo, we analysed PAH activity land-
scapes for full genotypes at a wide range of substrate and
cofactor concentrations. These conditions assessed PAH func-
tion in the context of metabolic and therapeutic states and mir-
rored major molecular mechanisms underlying missense
mutation-induced PKU; however, data obtained in vitro may
still differ from residual activity in patients.
We observed several patterns of changes in the architecture
of PAH activity landscapes and the combined evidence from
functional analyses with biochemical, clinical, and therapeutic
data delivered means to generate hypotheses about the
mechanisms behind individual genotypes. Changes in PAH
activity landscapes as regards to substrate concentrations may
impact dietary management. Some genotypes (p.[Arg261Gln];
[Arg261Gln], p.[Arg261Gln];[Arg408Trp], p.[Arg261Gln];
[Gln355_Tyr356insGlyLeuGln], p.[Arg297His];[Arg408Trp])
induced a right-shift of the activity landscape. As a conse-
quence, these genotypes are associated with very low enzyme
activity at low phenylalanine concentrations. On the one
hand, the enzyme is inactive at phenylalanine concentrations
<200 mM. On the other hand, the right-shift results in good
metabolic PAH function at higher phenylalanine concentra-
tions (peak activity, ∼800 mM phenylalanine). Therefore,
internationally accepted target phenylalanine concentrations
<360 mM in the patient may in these cases be difficult to
achieve. In turn, phenylalanine tolerance may be dispropor-
tionately higher at phenylalanine concentrations slightly above
the target, lowering the burden of diet. This has to be con-
firmed by clinical studies with appropriate analysis of dietary
phenylalanine intake and blood phenylalanine concentrations.
Notably, different dietary regimens leading to different meta-
bolic states may at least in part explain the significant pheno-
typic variability of homozygous p.Arg261Gln and p.
[Arg261Gln];[Arg408Trp] with respect to disease severity and
BH4 responsiveness (http://www.biopku.org) (see online sup-
plementary figure S5).20 32 In the experimental dataset pre-
sented here, the presence of the mutation p.Arg261Gln in the
genotype often induced broadening of the PAH working
range, with rather high enzyme activities at a wide range of
phenylalanine concentrations. This may be associated with
fewer phenylalanine fluctuations, known to be a major factor
of brain damage.33 Eight genotypes showed a narrow range of
L-phenylalanine concentrations associated with considerable
PAH activity. In three cases this was accompanied by a shift of
the area of peak PAH activity below 300 mM L-phenylalanine.
The carrier of such a genotype may need to keep blood
phenylalanine concentrations in a tight range to optimise
phenylalanine flux and could thus benefit from avoidance
of phenylalanine fluctuations.
Another group of genotypes induced changes in PAH activity
landscapes as regards to cofactor concentrations that may have
implications not only for pharmacological treatment with BH4.
Some genotypes showed PAH activity peaks at lower BH4 concen-
trations. Among these, the presence of the p.Arg261Gln mutation
was associated with inconsistent BH4 response, whereas the
mutation p.Arg408Trp led to consistent BH4 response. An activity
peak at increased BH4 concentrations was associated with the
occurrence of p.Gln355_Tyr356insGlyLeuGln. Moreover, geno-
types in this group also harboured mutations typically associated
with inconsistent clinical phenotypes (p.Leu48Ser, p.Ile65Thr, p.
Ala300Ser). Patients carrying these genotypes may need more
BH4 to achieve their optimal enzyme function. As a consequence
BH4 dosages used in standard BH4 response tests may be insuffi-
cient to achieve an increase of enzyme activity and decrease of
phenylalanine concentrations, the endpoint in response tests.
Interestingly, genotypes with loss of landscape architecture p.
[Gln355_Tyr356insGlyLeuGln];[Gln355_Tyr356insGlyLeuGln],
p.[Pro281Leu];[Gln355_Tyr356insGlyLeuGln] also contained p.
Gln355_Tyr356insGlyLeuGln and are associated with severe
BH4 non-responsive phenotypes. The apparent affinity of PAH
to BH4 in eukaryotic cells is ∼30 mM and peak PAH activity
was reached at 130 mM in our setting, which is in line with
values obtained from recombinant PAH.20 In addition, liver
cells keep BH4 at a concentration of about 9 mM.
34 Therefore,
the PAH system suffers from a constant shortage of BH4.
Oxidative stress35 or other environmental factors with negative
impact on BH4 availability may trigger PAH deficiency and thus
may further aggravate clinical phenotypes. Taken together,
alterations in BH4 demand may add to the molecular mechan-
isms underlying phenotypic variability related to both disease
severity and BH4 responsiveness.
Our results confirm the frequent observation that residual
PAH enzyme activity is not only the determinant as to the sever-
ity of the biochemical phenotype but also a prerequisite for BH4
response and thus correlates with it.9 However, this correlation
is not absolute. For instance, in group 3 genotypes with residual
enzyme activity >5%, we observed a significant proportion of
genotypes associated with little or no BH4 response. On the one
hand, they were associated with relatively low residual activity
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within this group; on the other hand, lack of response to cofac-
tor treatment was linked to a higher cofactor need. The defin-
ition of three groups provides a classification of genotypes with
different overall PAH enzyme activity that allows for a global
estimation of the severity of the disease. Beyond that, our study
revealed that PAH activity landscapes not only provide informa-
tion on the quantitative value of residual activity but also on the
position of enzyme activity in the metabolic and therapeutic
space, and that this is another important determinant of the
phenotype.
Inconsistent phenotypes in individuals carrying identical geno-
types are well known in clinical practice. In Leuders et al,36 five
patients carrying the genotype p.[Leu48Ser];[Leu48Ser] all
showed responsiveness at a low BH4 dosage. In databases, four
cases with non-responsive PAH deficiency (9%) and four cases
with slow response to BH4 (9%) are reported for individuals car-
rying this genotype (see online supplementary figure S5). These
observations, however, are not necessarily in contradiction to
each other. We observed a higher need for BH4 to achieve peak
activity for three genotypes containing the mutation p.Leu48Ser.
Notably, Leuders et al36 tested BH4 response after 7 days of treat-
ment. Repeated administration of BH4 may lead to constantly
elevated concentrations of cellular BH4 and thus provide the
variant PAH protein with a sufficient amount of cofactor, which
may explain the consistent positive response. On the other hand,
inconsistent BH4 responsiveness has previously been reported for
genotypes containing the p.Arg261Gln mutation.37 38 Following
our observation of a right-shifted area of peak activity with
respect to phenylalanine values for p.[Arg261Gln];[Arg408Trp],
the variability in the phenotype of patients carrying this genotype
may, at least in part, be due to fluctuations in substrate concentra-
tions, particularly with regard to blood phenylalanine concentra-
tions at the time of the BH4 loading test. As a conclusion for
these observations, the assessment of PAH activity landscapes
testing PAH function revealed how varying metabolic and thera-
peutic conditions may contribute to variability in the clinical
phenotype. Nevertheless, other genetic and non-genetic factors39
may also influence phenylalanine clearance and thus the clinical
phenotype in PKU patients. Among these, differences in the dis-
posal of excess phenylalanine by transamination when the
hydroxylation reaction is blocked, variation in the carrier-
mediated uptake of phenylalanine by the brain and the liver, and
environmental factors such as oxidative stress are the best recog-
nised modifiers to date.25 33 35 40–42
In conclusion, this work may exemplify how application of
molecular genetics translates into medical practice. It gives new
significance to gene analysis of the PAH locus in clinical routine
and shows the importance of considering full genotypes. The
analysis of activity landscapes in the metabolic and therapeutic
space provided clinically relevant new insights into
genotype-related impaired PAH function beyond the known link
between residual activity and clinical phenotype. In the presence
of specific genotypes we observed different patterns of activity
landscape architecture and established orienteering rules for
their interpretation. In addition, the work provides a web-based
tool to assist clinicians in clinical care of PKU patients (http://
pah-activitylandscapes.org). The web application allows for
retrieving country- and region-specific information on geno-
types and their related PAH function. Its sustainability and
increasing representativeness will be ensured by continuous
extension and updates as well as research on demand delivering
new PAH activity landscapes upon request.
The analysis of individual genotype-related PAH activity land-
scapes together with the information provided on genotype-
related clinical phenotypes may permit improved long term
phenotype prediction and the implementation of personalised
medicine strategies for dietary regimens and pharmacological
treatment.
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